Back to Journals » Cancer Management and Research » Volume 12

Overexpression of FAM234B Predicts Poor Prognosis in Patients with Luminal Breast Cancer

Authors Lyu L, Wang M, Zheng Y, Tian T, Deng Y, Xu P, Lin S, Yang S, Zhou L, Hao Q, Wu Y, Dai Z, Kang H

Received 2 September 2020

Accepted for publication 12 November 2020

Published 3 December 2020 Volume 2020:12 Pages 12457—12471


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Eileen O'Reilly

Lijuan Lyu,1,2,* Meng Wang,1,* Yi Zheng,1,2,* Tian Tian,1 Yujiao Deng,1,2 Peng Xu,1,2 Shuai Lin,1 Si Yang,1,2 Linghui Zhou,1,2 Qian Hao,1,2 Ying Wu,1,2 Zhijun Dai,2 Huafeng Kang1

1Department of Oncology, The 2nd Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, People’s Republic of China; 2Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Huafeng Kang
Department of Oncology, The 2nd Affiliated Hospital of Xi’an Jiaotong University, West 5th Road, Xincheng District, Xi’an 710004, People’s Republic of China
Zhijun Dai
Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, No. 79, Qingchun Road, Hangzhou 310003, People’s Republic of China

Background: Family with sequence similarity 234 member B (FAM234B), a protein-coding gene, is mainly expressed in brain tissues. Its clinical significance and biological function in tumors, especially in breast cancer (BC), have not been elucidated.
Methods: We firstly investigated the expression pattern of FAM234B at the mRNA and protein levels using Oncomine, TCGA portal, GEPIA, TIMER, HPA, and UALCAN databases, then applied bc-GenExMiner to assess the associations between expression level of FAM234B and clinicopathological features of BC. Besides, we also verified the expression of FAM234B expression in clinical BC samples using qRT-PCR. Subsequently, GEPIA, bc-GenExMiner, and TIMER databases were used to analyze the prognostic significance of FAM234B in all BC and different molecular subtypes. Finally, we conducted co-expression analysis and gene set enrichment analysis (GSEA). Additionally, we explored the regulatory mechanism of FAM234B in BC.
Results: Both bioinformatics analysis and experimental verification confirmed that the FAM234B expression was significantly higher at the mRNA and protein levels in luminal BC tissues than in adjacent normal tissues. High FAM234B expression was significantly correlated with older age, estrogen receptor-positive, progesterone receptor-positive, human epidermal growth factor receptor 2-negative, wild-type p53, low Nottingham prognostic index, low Scarff-Bloom-Richardson grade, lymph node metastasis positivity, and high tumor stage. Moreover, survival analysis indicated that high FAM234B expression was significantly related to a worse prognosis in patients with luminal BC. GSEA indicated that FAM234B was positively related to membrane transport process and negatively associated with immune response function. Besides, mechanism exploration indicated that pseudogene HTR7P1 might act as endogenous RNA to compete with has-miR-1271-5p or has-miR-381-3p for binding to FAM234B, thereby upregulating the expression of FAM234B in luminal BC.
Conclusion: Our results suggest that FAM234B may be a candidate therapeutic target or prognostic marker for luminal breast cancer.

Keywords: FAM234B, luminal breast cancer, HTR7P1, prognosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]